linjc16/ctgov huggingface dataset:
Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Clinical Core

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to provide comprehensive longitudinal assessments of a cohort of PD patients before, during, and after DBS surgery, including neurological, neurophysiological, and neuropsychological data.

Official Title
-----------------
Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Clinical Core

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 21 years and older Diagnosis of Parkinson's disease Candidate for DBS Exclusion Criteria: Diagnosis of dementia Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observational|Observational study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Registry | This is a registry of patients undergoing DBS surgery. The goal of this project is to provide comprehensive longitudinal assessments of a cohort of PD patients before, during, and after DBS surgery, including neurological, neurophysiological, and neuropsychological data. | 5 Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's Disease
Minimal Erythema Dose of UV-B in Normal Population of Taiwan

Study Overview
=================
Brief Summary
-----------------
There is no previous study on the minimal erythema dose of UVB irradiation in Chinese people. We will investigate the correlation of skin phototype, constitutive skin color, facultative skin color and minimal erythema dose in Taiwanese.

Detailed Description
-----------------
The skin phototype will be obtained from a structuralized questionaire. The constitutive skin color and facultative skin color will be obtained by chromameter. The minimal erythema dose will be obtained by physician's assessment.

Official Title
-----------------
Minimal Erythema Dose of UV-B in Normal Population of Taiwan

Conditions
-----------------
Human Volunteers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 10-65 years old normal healthy volunteers Exclusion Criteria: Age under 10 years old or older than 65 years old People with a past history of photo-sensitivity People who had been treated with phototherapy

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
minimal erythema dose, UVB, normal
Evaluation of Pancreatic Duct Stenting in Patients With Pancreatic Pseudocysts.

Study Overview
=================
Brief Summary
-----------------
The disruption of the pancreatic duct seems to be a major cause pseudocyst formation and persistence in patients suffering from acute/chronic pancreatitis. No prospective randomized studies have been conducted on the influence of pancreatic duct stenting for the patients' benefits and recurrence rates. The aim fo this study is therefore to evaluate prospectively in a randomized, controlled fashion in patients wit pancreatic pseudocysts, wether pancreatic duct stenting of a disrupted pancreatic duct is beneficial in terms of quicker clinical recovery and avoidance of recurrence of pancreatic pseudocysts.

Official Title
-----------------
Randomized Multicenter Study on Pancreatic Duct Stenting in Disrupted or Obstructed Ducts in Context With Endoscopic Treatment of Pancreatic Pseudocysts.

Conditions
-----------------
Chronic Acute Pancreatitis

Intervention / Treatment
-----------------
* Procedure: pancreatic duct stenting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pancreatic pseudocyst, at least 6 cm in diameter symptomatic pancreatic pseudocyst increasing size of pancreatic pseudocyst within 6 weeks Exclusion Criteria: Pregnancy Age less than 18 years Postoperative status preventing access to papilla Allergy to contrast preventing from ERP Missing informed consent to study PTT above 1.5 times of normal, unless substituted Platelet count less than 50.000/µl, unless substituted Pancreatic ascites or fistula Life expectancy less than 2 years Percutaneously drained cysts are not part of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: No stenting<br>Control group, no stenting of the pancreatic duct in case of a disrupted duct | |
| Active Comparator: Pancreatic duct stenting<br>in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm | Procedure: pancreatic duct stenting<br>* in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of pancreatic pseudocyst |  | two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
disrupted duct, pancreatic pseudocysts
A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Study Overview
=================
Brief Summary
-----------------
This single arm study will assess the long-term maintenance of hemoglobin levels, safety and tolerability of once-monthly intravenous administration of Mircera in hemodialysis patients with chronic renal anemia. Patients currently receiving darboepoetin alfa or epoetin alfa maintenance treatment will receive intravenous Mircera at a starting dose of 120, 200 or 360 micrograms/4 weeks (based on the ESA dose administered on week-1). Subsequent doses will be adjusted to maintain hemoglobin levels within the target range of 10.5-12.5g/dL. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Official Title
-----------------
An Open Label Study to Assess the Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Monthly Administration of Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Conditions
-----------------
Anemia

Intervention / Treatment
-----------------
* Drug: methoxy polyethylene glycol-epoetin beta


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients, >=18 years of age; chronic renal anemia; regular long-term hemodialysis therapy with the same mode of dialysis for >=3 months; continuous iv or sc maintenance ESA treatment during previous 2 months. Exclusion Criteria: transfusion of red blood cells during previous 2 months; significant acute or chronic bleeding, such as overt gastrointestinal bleeding; active malignant disease (except non-melanoma skin cancer).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: methoxy polyethylene glycol-epoetin beta<br>* 120, 200 or 360 micrograms / 4 weeks iv (starting dose)<br>* Other names: Mircera;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients maintaining average Hb concentration within target range during evaluation period |  | Weeks 17-24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Hb concentration between reference and evaluation period; mean time spent in, and percentage of patients maintaining Hb within target range |  | Weeks 17-24 | 
| Dose adjustments; RBC transfusions |  | Throughout study | 
| AEs, laboratory parameters, vital signs |  | Throughout study |
A Single-Center Pilot Study to Assess Macular Function

Study Overview
=================
Brief Summary
-----------------
This study seeks to evaluate a novel endpoint for future dry AMD clinical trials.

Conditions
-----------------
Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects in good health aged 20-29 or 60-90 years (normal cohorts) Subjects with early non-exudative age-related macular degeneration (AMD cohort) Exclusion Criteria: Enrollment in a investigational drug or device study and have used an investigational drug or device within 7 days of enrollment into this study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AMD<br> | |
| Young normals<br> | |
| Older normals<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-exudative age-related macular degeneration
Histological Evaluation in the Efficacy of GentleWave in Root Canal Pulp Tissue Debridement and Disinfection of Difficult to Reach Areas in Mandibular Human Molars II. An In-vivo Study.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand and learn better the efficacy of GentleWave and obtain histological evidence of the efficacy of this new technology done in-vivo

Official Title
-----------------
Histological Evaluation in the Efficacy of GentleWave in Root Canal Pulp Tissue Debridement and Disinfection of Difficult to Reach Areas in Mandibular Human Molars II. An In-vivo Study.

Conditions
-----------------
Root Canal Treatment

Intervention / Treatment
-----------------
* Device: GentleWave


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Only teeth that patient decided to have the extraction done instead of having any other type of dental treatment and teeth extracted at patient's petition. Exclusion Criteria: Teeth with root fractures or previously root canal treated teeth. Teeth with severe loss of structure Children

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Partial root canal treatment with the Sonendo GentleWave<br> | Device: GentleWave<br>* Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visualization of the amount of pulp tissue left behind after GentleWave procedure | Visualization of the amount of pulp tissue left behind after GentleWave procedure as assessed by reviewing the histological serial sections under the light microscope | at the time of tooth extraction(immediately after GentleWave procedure) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with the presence of bacteria inside the root canal and inside the dentinal tubules as assessed by observation under the light microscope |  | at the time of tooth extraction(immediately after GentleWave procedure) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GentleWave, Multisonication, Sonendo
Antalgic Effects of Well-being Treatments in Cancer Care

Study Overview
=================
Brief Summary
-----------------
observational , Monocentric, study to assess antalgic effects of well-being treatment in cancer care.

Detailed Description
-----------------
Contrary to supportive care, well-being care is imperfectly assessed. Well being care (WBC) consist on complementary programs, with no real consensus. Very few studies have rigorously evaluated its benefits The objective of this study was to evaluate the impact of four well-being treatments (foot reflexology, socio-aesthetics, Sophrology and singing) provided in a healthcare facility

Official Title
-----------------
Antalgic Effects of Well-being Treatments in Cancer Care; Foot Reflexology, Socio-aesthetics, Sophrology, Singing

Conditions
-----------------
Cancer, Cancer Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all type of cancer treated at the general Hospital of Valence patient agree to participate on Well being session: foot reflexology, socio-aesthetics, Sophrology and singing Age ≥ 18 years Affiliation to a Social security system Patient who has given written consent signed before any specific procedure of the protocol Exclusion Criteria: Patient under guardianship, deprived of liberty, safeguard of justice Patient presenting a serious psychiatric pathology that does not allow compliance with the completion of the scale (at the discretion of the investigator) Refusal to participate in research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assesment | numerical scale 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. | 1 immediately before well being treatment | 
| Pain assesment | numerical scale 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. | 1 immediately after well being treatment |
RENAL RESISTIVE INDEX POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY?

Study Overview
=================
Brief Summary
-----------------
An observational trial aiming to verify whether does any relationship exist between renal resistive index and postoperative outcome in major high risk surgery

Detailed Description
-----------------
Renal resistive index was measured just after major high risk operations and then patients were observed searching for any surgical and medical-related complications during the first post-operative week

Official Title
-----------------
MAY RENAL RESISTIVE INDEX BE AN EARLY PREDICTIVE TOOL OF POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY?

Conditions
-----------------
Major High Risk Operations, Renal Resistive Index, Outcome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years major surgical operations Exclusion Criteria: age < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Renal resistive Index<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications | Recording any postoperative complication occurred within the first postoperative week | 7 post-operative days |
Atkins Diet for Difficult-to-Control Headaches in Teenagers

Study Overview
=================
Brief Summary
-----------------
This is a 3-month pilot study of 10 adolescents with chronic daily headache. Teens will be placed on a modified Atkins diet and followed with 2 subsequent visits to assess for headache improvement.

Detailed Description
-----------------
Patients are placed on the diet and followed with various measures for 3 months. If the diet is helpful it is continued. Patients are still being enrolled as of 9/6/06.

Official Title
-----------------
Use of the Atkins Diet for Adolescents With Chronic Daily Headache.

Conditions
-----------------
Chronic Daily Headache

Intervention / Treatment
-----------------
* Behavioral: Modified Atkins diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 12-19 Minimum 15 headaches/month for at least 3 months Tried 2 preventative medications previously Exclusion Criteria: Prior use of the Atkins diet for more than 1 week Pregnancy Significant heart or kidney disease Dangerously underweight Using acute pain medications more than 11 days in the past month Medications being changed

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Modified Atkins diet|15 grams of carbohydrates per day - high fat diet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Headaches |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ketosis |  | 3 months | 
| Diet duration |  | as long as tolerated | 
| Quality of life (PedsMIDAS) |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
headache, Atkins, ketosis, intractable
Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene

Study Overview
=================
Brief Summary
-----------------
The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants of the melatonin receptor 1B gene will be evaluated. The following will be done at 0 and 3 months: OGTT questionnaires about sleep and activity Actigraph Anthropometry Blood pressure

Detailed Description
-----------------
http://www.sciencedirect.com/science/article/pii/S1550413116301607

Official Title
-----------------
Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?

Conditions
-----------------
Diabetes, Glucose Tolerance

Intervention / Treatment
-----------------
* Drug: Melatonin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signed informed concent Known genotype for MTNR1B from the Botnia-ppp study Age 18-75 years Exclusion Criteria: Diabetes Positive GAD-ab Sever dysregulated hypertension glaucoma severe coronary heart disease or arrythmias previous or ongoing severe ventricle or duodenal ulcer psychosis or anxiety disorder regular use of sleep pills, antidepressants or neuroleptics creatinine > 130 µmol/L elevated liver enzymes (ASAT, ALAT, ALP, GT, bilirubin) > 3 times reference value inability to sign informed concent other factor with according to the physician may affect treatment or results. participation in other clinical study allergy to melatonin or other substance in the capsule hereditary galactose intolerance or glucose/galactose malabsorption intention to become pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Melatonin<br>melatonin 4mg od for 3 months | Drug: Melatonin<br>* All subjects receive the same dose of melatonin<br>* Other names: Circadin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose tolerance | Glucose tolerance is measured in OGTT: 0,30,60,90 and 120 minute values of glucose and insulin. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sleep | monitoring of sleep with questionnaires and activity monitoring | 3 months | 
| Activity | Activity and sleep of the subjects is recorded with Actigraph at 0 and 3 months | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, melatonin, glucose tolerance, sleep